AdaptHealth Corp. (NASDAQ: AHCO) shares fell as much as 26% after the Company reported second quarter revenue of $740.3 million, well below approximately $847 million expected, a GAAP loss driven in part by a $144.2 million goodwill impairment charge, and a substantial reduction to full-year guidance. If you suffered a loss on your AdaptHealth investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Adjusted EBITDA came in at $132 million for the quarter, against roughly $160 million expected. Alongside those results, AdaptHealth reset its 2026 continuing-operations outlook to approximately $2.85 billion to $2.89 billion in revenue and $490 million to $520 million in adjusted EBITDA. Management attributed the reset to the Diabetes Health divestiture, a capitated contract, manufacturer pricing, and other portfolio actions.
The investigation concerns the scale of that exposure. The reduced revenue range represents a decline of roughly 16% to 19% from the guidance figures the Company had carried weeks earlier.
Shareholders who lost money on AHCO are encouraged to submit their loss information here or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the AHCO Investigation
Q: What is the AHCO investigation about? A: A securities investigation is pending concerning AdaptHealth Corp. (NASDAQ: AHCO) regarding potentially materially false or misleading statements. Shares fell as much as 26% after the Company reported Q2 revenue of $740.3 million, a $0.99 GAAP loss, a $144.2 million goodwill impairment, and a sharply reduced 2026 outlook, causing losses for shareholders.
Q: How much did AHCO stock drop? A: Shares declined as much as 26% following the Q2 results and the reset of 2026 revenue guidance to approximately $2.85 billion to $2.89 billion. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek recovery.
Q: Who is eligible to participate in the AHCO investigation? A: Investors who purchased AHCO stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do AHCO investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my AHCO shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AHCO and sold at a loss may still participate in the investigation.
Q: What if my AHCO losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no upfront fees, no retainer, and no out-of-pocket costs.
Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260807206328/en/